Gemina Laboratories Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GLABF research report →
Companywww.geminalabs.com
Gemina Laboratories Ltd. , a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company develops novel surface functionalization chemistries for the detection of pathogens and biomarkers.
- CEO
- Robert Crandall Greene
- IPO
- 2022
- Employees
- 6
- HQ
- Burnaby, BC, CA
Price Chart
Valuation
- Market Cap
- $3.83M
- P/E
- -1.57
- P/S
- 422.34
- P/B
- -0.89
- EV/EBITDA
- -1.74
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -219.61%
- Op Margin
- -26104.51%
- Net Margin
- -26928.44%
- ROE
- 62.39%
- ROIC
- 57.93%
Growth & Income
- Revenue
- $21.50K · 0.00%
- Net Income
- $-2,342,251 · 42.50%
- EPS
- $-0.03 · 44.18%
- Op Income
- $-2,237,705
- FCF YoY
- 60.12%
Performance & Tape
- 52W High
- $0.74
- 52W Low
- $0.04
- 50D MA
- $0.05
- 200D MA
- $0.16
- Beta
- -0.07
- Avg Volume
- 84.48K
Get TickerSpark's AI analysis on GLABF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our GLABF Coverage
We haven't published any research on GLABF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GLABF Report →